The Retimax reportedly performs innovative tests for the early screening and follow-up of important pathologies like Glaucoma, age related Maculopaty, vascular retinal degeneration and other optic nerve diseases. Paradigm will also distribute additional ophthalmic products in the international and domestic markets.
Stephen Davis, president of Paradigm Medicals, said: “This new partnership will create many new opportunities for both organizations. We are excited to be chosen as CSO’s exclusive distributor of their Retimax product in the domestic markets, we expect to do very well in the US. This new partnership will also open up new doors for future cooperative product development.”